Evidence-based approach to the introduction of positron emission tomography in Ontario, Canada

Journal of Clinical Oncology

Volumn 27, Issue 33, 2009, Pages 5607-5613

  Evans, William K ^a   Laupacis, Andreas ^a   Gulenchyn, Karen Y ^a   Levin, Les ^a   Levine, Mark ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANADA; CANCER REGISTRY; CLINICAL RESEARCH; EVIDENCE BASED MEDICINE; MEDICAL TECHNOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; CLINICAL TRIAL; ECONOMICS; FEMALE; FORECASTING; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; MALE; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PUBLIC HEALTH; REGISTER; REVIEW; STANDARD; UTILIZATION REVIEW;

CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; FEMALE; FORECASTING; HEALTH CARE COSTS; HEALTH PLANNING; HUMANS; MALE; MEDICAL ONCOLOGY; NATIONAL HEALTH PROGRAMS; ONTARIO; POSITRON-EMISSION TOMOGRAPHY; REGISTRIES;

EID: 73949105585     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.1614     Document Type: Article

References (36)

1. Houn F: Review of F-18 fluoro-2-deoxyglucose (F-18 FDG) positron emission tomography in the evaluation of malignancy. www.fda.gov/ohrms/dockets/dockets/ 98d0266/ref0001m.DOC
2. Som P, Atkins HL, Bandoypadhyay D, et al: A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): Nontoxic tracer for rapid tumor detection. J Nucl Med 21:670-675, 1980
3. Rigo P, Paulus P, Kaschten BJ, et al: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23:1641-1674, 1996
4. Medical Advisory Secretariat: Positron emission tomography for the assessment of myocardial viability. http://www.health.gov.on.ca/english/ providers/program/mas/tech/reviews/sum-petmyo-100105.html
5. Rajendran JG, Greer BE: Expanding role of positron emission tomography in cancer of the uterine cervix. J Natl Compr Canc Netw 4:463-469, 2006
6. Institute for Clinical Evaluative Sciences: Health technology assessment of positron emission tomography (PET) in oncology: A systematic review. http://www.ices.on.ca/file/Health-Technology-Assessment-PET-May-2001.pdf
7. Health Canada: Regulatory requirements for positron-emitting radiopharmaceuticals. http://hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/pdf/ brgtherap/pol-pers-prep-e.pdf
8. Pritchard KP, Julian J, McCready D, et al: A prospective study evaluating 18F-fluorodeoxyglucose (18FDG) positron emission tomography (PET) in the assessment of axillary nodal spread in women undergoing sentinel lymph node biopsy (SLNB) for breast cancer. J Clin Oncol 26:14s, 2008 (suppl; abstr 533)
9. Maziuk D, Darling GE, Inculet RI, et al: A randomized controlled trial (RCT) of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus conventional imaging (CI) in staging potentially resectable non-small cell lung cancer (NSCLC). J Clin Oncol 26:739s, 2008 (suppl; abstr 7502)
10. Ung YC, Maziak DE, Vanderveen JA, et al: 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: A systematic review. J Natl Cancer Inst 99:1753-1767, 2007
11. Fischer BM, Mortensen J, Hojgaard L: Positron emission tomography in the diagnosis and staging of lung cancer: A systematic, quantitative review. Lancet Oncol 2:659-666, 2001
12. Gould MK, MacLean CC, Kuschner WG, et al: Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA 285:914-924W, 2001
13. 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 86:3779-3786, 2001
14. Facey K, Bradbury I, Laking G, et al: Positron emission tomography (PET) imaging in cancer management: Ultra rapid review. Health Technology Assessment. Southampton, United Kingdom, National Health Service Research and Development Programme, 2004
15. Hain SF: Positron emission tomography in uro-oncology. Cancer Imaging 5:1-7, 2005
16. Huebner RH, Park KC, Shepherd JE, et al: A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 41:1177-1189, 2000
17. Laupacis A, Evans W: Diagnostic imaging in Canada. Healthc Pap 6:8-15, 2005
18. Institute for Clinical Evaluative Sciences: Health technology assessment of positron emission tomography (PET) in oncology: A systematic review. http://www.ices.on.ca/file/Feb2003-2.pdf
19. Institute for Clinical Evaluative Sciences: Health technology assessment of positron emission tomography (PET) in oncology: A systematic review. http://www.ices.on.ca/file/Health%20technology%20 assessment%20of%20Positron%20Emission%20 Tomography%20(PET)%20in%20Oncology%20-% 20A%20systematic%20review-2003[1].pdf
20. Institute for Clinical Evaluative Sciences: Health technology assessment of positron emission tomography (PET) in oncology: A systematic review. http://www.ices.on.ca/file/ACF17B.pdf
21. Institute for Clinical Evaluative Sciences: Health technology assessment of positron emission tomography (PET) in oncology: A systematic review. http://www.ices.on.ca/file/Pet-jan20041.pdf
22. Institute for Clinical Evaluative Sciences: Health technology assessment of positron emission tomography (PET) in oncology: A systematic review. http://www.ices.on.ca/file/Pet-report-Apr-2004[1].pdf
23. Ontario Association of Nuclear Medicine: CSNM Motions, May 2005. http://www.oanm.ca/download/CANM.CSNM-Motions-052005.pdf
24. Ung YC, Ling A, Sun A, et al: The impact of positron emission tomography (PET) in stage III non-small cell lung cancer: A prospective randomized clinical trial-Improving clinical trials accrual using screening log evaluations. Radiother Oncol 80:169, 2006 (suppl 1, abstr)
25. Antunes P, Bernard M-C, Stewart M: The 2007 Ontario budget: A balanced budget...but health care spending growth worrisome. http://sso.conferenceboard. ca/documents.aspx?did=1947
26. Medicare's coverage with evidence development: A policy making tool in evolution. J Oncol Pract 3:296-301, 2007
27. Tunis SR, Pearson SD: Coverage options for promising technologies: Medicare's "coverage with evidence development." Health Aff 226:1218-1230, 2006
28. Lindsay MJ, Siegel BA, Tunis SR, et al: The National Oncologic PET Registry: Expanded Medicare coverage for PET under Coverage with Evidence Development. AJR Am J Roentgenol 188: 1109-1113, 2007
29. Hillner BE, Siegel BA, Liy D, et al: Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the National Oncologic PET Registry. J Clin Oncol 26:1-8, 2008
30. National Emphysema Treatment Trial Research Group: A randomized trial: Comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348:2059-2073, 2003
31. Tunis SR, Carino TV, Williams RD, et al: Federal initiatives to support rapid learning about new technologies. Health Aff 26:140-149, 2007
32. van Tinteren H, Hoekstra OS, Smit EF, et al: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomized trial. Lancet 359:1388-1393, 2002
33. Herder GJ, Kramer H, Hoekstra OS, et al: Traditional versus up-front (18F) fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: A Dutch cooperative randomized study. J Clin Oncol 24:1800-1806, 2006
34. Wiering B, Oyen W, van der Sijp J, et al: Improved selection of patients for hepatic surgery of colorectal liver metastases with FDG-PET: A randomized trial. J Clin Oncol 26:179, 2008 (suppl 15S; abstr 4004)
35. Viney RC, Boyer MJ, King MT, et al: Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 22:2357-2362, 2004
36. National Cancer Research Network. A framework for PET research in the UK: Report of the NCRI PET strategic planning group. www.ecmcnetwork.org.uk/ecmc/ pdfs/PET-ECMC.pdf